JNCCN 360

Editor:

David S. Ettinger, MD

Advertisement

Advertisement

Edward B. Garon, MD, on Capmatinib in METex14-Mutated Advanced NSCLC: Expert Perspective

Suresh S. Ramalingam, MD, on Clinical Implications of Using Nivolumab Plus Ipilimumab in First-Line NSCLC

Roy S. Herbst, MD, PhD, on Osimertinib for NSCLC: Clinical Implications of a Potentially Practice-Changing Finding

Recent

Interim Results of Trastuzumab Deruxtecan in HER2-Mutated Metastatic NSCLC

AACR II: Flat Dosing of Nivolumab in Patients Previously Treated for NSCLC

HER2-Targeted Therapy With Trastuzumab Deruxtecan in Lung Cancer

AACR II: Potential Link Between Lung Cancer Risk and Sleep Patterns

Published

Medical Literature

Tumor-Infiltrating Lymphocytes in Metastatic Lung Cancer

EML4-ALK Mutations and Lorlatinib Treatment in Lung Cancer

Does Patients' Knowledge of Lung Cancer Diagnosis Improve Survival Outcomes?

Beyond Skin Cancer: BRAF Inhibition in Solid Tumors Including Lung Cancer

Ongoing

Advanced Non-Small Cell Lung Ccancer Patient Management Simulator

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Lung Cancer

Time to Tailor NSCLC RT to Spare the Immune System?

Visiting Professors: Lung Cancer Edition, Issue 1, 2019

Available

Clinical Trials

The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Mayo Clinic Cancer Center

University of Michigan Comprehensive Cancer Center

Roswell Park Cancer Institute

NCCN Resources

Copyright © 2020 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.